Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study is an open, multicenter, dose-increasing/dose-expanding/efficacy expanding Phase I
clinical study aimed at evaluating the tolerance, safety, PK, PD, and immunogenicity of
SHR-5495 in the treatment of advanced malignant tumor patients, and preliminarily observing
its anti-tumor efficacy. The entire study was divided into three stages: dose escalation,
dose extension, and efficacy extension.